



Leeland Ekstrom, PhD, COO of Nashville Biosciences said, "In-depth genetic analysis has become essential in life science R&D. With drug development costs forecast to double every nine years, we need more than ever to improve R&D productivity and uncover new ways to diagnose and care for diseases more efficiently. Working with BC Platforms' will extend the impact of BioVU to support researchers in efficient drug and diagnostics discovery and development, while still protecting the integrity of the biobank and the data it has been entrusted with."

Tero Silvola CEO of BC Platforms commented, "The creation of Nashville Biosciences as the commercial interface by VUMC to allow streamlined access to one of the world's largest and most unique datasets was a very progressive move. Using our BCRQUEST.com platform, biobanks can select which data from their collections to showcase in a secure and compliant manner to the world's largest pharmaceutical R&D teams in order to establish future research projects. The life science industry benefits from this global pool of harmonized biobank data - now totaling two million subjects - to gain scientific insights with the goal of reducing drug development timelines and bringing benefits to patients worldwide."